



Channelopathies in fragile X syndrome

Pan-Yue Deng and Vitaly A. Klyachko

Abstract | Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and the leading monogenic cause of autism. The condition stems from loss of fragile X mental retardation protein (FMRP), which regulates a wide range of ion channels via translational control, protein–protein interactions and second messenger pathways. Rapidly increasing evidence demonstrates that loss of FMRP leads to numerous ion channel dysfunctions (that is, channelopathies), which in turn contribute significantly to FXS pathophysiology. Consistent with this, pharmacological or genetic interventions that target dysregulated ion channels effectively restore neuronal excitability, synaptic function and behavioural phenotypes in FXS animal models. Recent studies further support a role for direct and rapid FMRP–channel interactions in regulating ion channel function. This Review lays out the current state of knowledge in the field regarding channelopathies and the pathogenesis of FXS, including promising therapeutic implications.

Macroorchidism

A condition in which males have abnormally large testes.

Channelopathies

A heterogeneous group of disorders resulting from the dysfunction of ion channels, which can be caused by mutations either in genes encoding channels themselves or in related factors that regulate ion channels.

Hyperexcitability

An abnormal state of a neuron characterized by increased probability of firing action potentials in response to an input.

Fragile X syndrome (FXS) is the leading monogenic cause of intellectual disability and autism. Affecting both males (~1/4,000) and females (~1/5,000–8,000), FXS is typically associated with cognitive dysfunction (language delay, intellectual disabilities, learning deficits), social and behavioural problems (anxiety, autism spectrum disorders (ASDs)), neurological deficits (seizures, abnormal sleep patterns) and morphological abnormalities (dysmorphic faces and macroorchidism)¹. The syndrome is caused by loss of fragile X mental retardation protein (FMRP), which most commonly results from the expansion of an unstable triplet CGG-repeat motif (>200 repeats) located within the 5' untranslated region of the *FMR1* gene on the X chromosome. This expansion causes gene hypermethylation and transcriptional silencing. Rare mutations in *FMR1* that result in 'loss-of-function FMRP' have also been linked to FXS².

Increasing evidence suggests that the symptoms of FXS stem from disruptions in neuronal activity³. Indeed, FMRP, with its multiple RNA-binding and protein–protein interaction domains (BOX 1), is highly expressed throughout the nervous system⁴. It is involved in a broad range of physiological functions, including genome stabilization, RNA editing, pre-RNA splicing, regulation of cell differentiation and modulation of ion channel function, neuronal excitability and synaptic plasticity. Specific to ion channel function, FMRP works through multiple direct and/or indirect mechanisms to control channel expression and activity^{3,5,6} (TABLE 1). Indeed, many types of ion channel are dysfunctional in *Fmr1* knockout (KO) models, including voltage-dependent ion channels (sodium (Na⁺) channels, potassium (K⁺) channels, calcium (Ca²⁺) channels and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels),

voltage-independent ion channels (small-conductance Ca²⁺-activated K⁺ (SK) channels) and ligand-gated ion channels (ionotropic glutamatergic and GABAergic receptors). Although these abnormalities are not caused by genetic mutations in the ion channel genes themselves, we broadly refer here to these ion channel dysfunctions as channelopathies. At the functional level, these channelopathies contribute to neuronal and network hyperexcitability, cognitive dysfunction and behavioural abnormalities, all of which are part of FXS pathophysiology (FIG. 1). In this Review, we first summarize evidence of hyperexcitability at the behavioural, circuit, cellular and synaptic levels in FXS. We then present findings in support of channelopathies underlying these excitability-related defects, including key molecular mechanisms. Finally, we discuss implications for future therapeutic strategies targeting ion channels in FXS.

Evidence of hyperexcitability in FXS

The clinical phenotypes of FXS are quite complex and vary considerably across individuals. However, most exhibit neurological symptoms indicative of network hyperexcitability, including seizures, hyperarousal, hyperactivity and hypersensitivity to sensory stimuli⁷. Neuronal hyperexcitability is also consistently observed in FXS animal models, data from which indicate intrinsic hyperexcitability and/or excitation/inhibition imbalance in neuronal circuits^{3,8,9}. We summarize the findings from both human patients and animal models below.

Behavioural abnormalities/symptoms

Epilepsy — an outward expression of circuit-level hyperexcitability — occurs in 10–20% of individuals with FXS. Seizure patterns on electroencephalography


Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO, USA.

✉e-mail: klyachko@wustl.edu

<https://doi.org/10.1038/s41583-021-00445-9>

Box 1 | FMRP functional domains

The multi-domain structure of fragile X mental retardation protein (FMRP) enables it to modulate the functions of ion channels through multiple mechanisms, including regulation of channel translation, surface expression and/or gating dynamics, or by indirectly regulating channel activity through second messenger signalling pathways. FMRP is a protein of 632 amino acids with a molecular weight of ~80 kDa. The amino-terminal domain (amino acids 1–202) contains two Tudor (Agenet) domains — AG1 (amino acids 3–49) and AG2 (amino acids 63–113), both of which are involved in protein–protein interactions — one nuclear localization signal (amino acids 115–154) and one K homology domain (KH0, amino acids 126–202). The central domain (amino acids 203–404) comprises the KH1 (amino acids 216–280) and KH2 (amino acids 281–404) motifs that mediate RNA binding. The carboxy-terminal domain contains the RGG box (amino acids 527–552), a high-affinity RNA-binding domain that interacts with G-quadruplex RNAs and is essential for FMRP’s association with polyribosomes. The C terminus also harbours a low-complexity domain (amino acids 466–632), which can promote dynamic interactions with proteins and RNAs. The low-complexity domain is implicated in the formation of ribonucleoprotein particles. The figure shows the FMRP functional domains¹⁵⁸ (three major domains colour-coded, numbers indicate position within the amino acid sequence).



typically present as benign focal epilepsy of childhood¹⁰, although many affected individuals continue to have seizures after the age of 20 years¹¹. Patients with FXS are also hyperresponsive to sensory stimulation and display tactile defensiveness^{12,13}. Sensory hyperreactivity can cause a hyperaroused state characterized by disruptions in circadian rhythms, including frequent awakenings from sleep^{14,15}. The seizures and hyperresponsivity are recapitulated in FXS models¹⁶; *Fmr1* KO mice have a lower threshold for audiogenic seizures^{17–23}, hypersensitivity to sensory stimuli^{24–26} and hyperactivity^{27–29}.

Circuit and network dysfunctions

Increased excitability at the network level has been measured in patients using various non-invasive techniques. For example, electroencephalography abnormalities are commonly observed in individuals with FXS^{11,15,30}, including centro-temporal spikes, slowed background rhythm and multifocal epileptiform discharges. Sensory hypersensitivity is also apparent in the elevated amplitude of evoked potentials in response to auditory and/or visual stimuli³¹, including heightened event-related brain potentials within the auditory cortex of children with FXS³². Looking into the mechanisms of cortical network hyperexcitability in individuals with FXS, Morin-Parent et al.⁹ used transcranial magnetic stimulation to show that patients with FXS have significantly reduced short-interval intracortical inhibition (mediated by GABA_A receptors (GABA_ARs)), increased long-interval intracortical inhibition (mediated by GABA_B receptors) and increased intracortical facilitation (mediated by glutamatergic receptors) compared with healthy controls. Overall, the data support loss of FMRP leading to network hyperexcitability, hypersensitivity to sensory stimuli and excitation/inhibition imbalance.

Some of the specific neurological symptoms associated with FXS are also indicative of circuit dysfunction

in particular brain regions. For example, tactile defensiveness, learning and memory deficits, fear and anxiety — all of which are common in FXS — can be linked to circuit/network abnormalities in the somatosensory cortex, hippocampus or amygdala, respectively. Data from FXS animal models confirm the presence of circuit abnormalities and marked excitation/inhibition imbalance in these regions. In the somatosensory cortex of *Fmr1* KO mice, circuit hyperexcitability manifests as prolonged UP states^{33–35}. Studies also find elevated cortical network synchrony in layer 2/3 of the barrel cortex³⁶, whereas network inhibition during the UP states is less synchronous³³. Also using this model, Domanski et al. observe diminished feedforward inhibition and increased excitation/inhibition ratio during trains of activity in layer 4 barrel cortex neurons³⁷. Similar network excitation/inhibition imbalance is also observed in the primary visual cortex³⁸ and auditory brain stem^{39–41} of FXS animal models. In the hippocampal circuits of *Fmr1* KO mice, hyperexcitability manifests in elevated epileptiform activity^{42,43} as well as abnormally high spiking probability and reduced spiking precision in hippocampal feedforward inhibitory circuits^{44,45}. These defects are associated with a marked shift in excitation/inhibition circuit balance, primarily a result of reduced activity of feedforward inhibitory hippocampal interneurons. In the amygdala of *Fmr1* KO mice, although the overall excitation/inhibition balance appears to be maintained, the temporal window of peak excitation to peak inhibition is significantly narrower as a result of reduced tonic GABA_AR-mediated inhibition^{46,47}. This narrowing leads to circuit hyperexcitability and abnormal amygdala functions^{46,48–50}.

Collectively, these data support the presence of hyperexcitable circuits and networks in individuals with FXS and animal models, some of which may underlie characteristic FXS symptoms.

Synaptic and cellular defects

Some of the behavioural-level and network-level hallmarks of FXS are driven by cellular and synaptic mechanisms. There is now extensive evidence of changes in synaptic transmission and plasticity as well as dysregulated cellular excitability in FXS. For example, in animal models, neurons across multiple brain regions exhibit an abnormally high action potential firing rate, including in the hippocampus, somatosensory cortex, entorhinal cortex and auditory brainstem^{33,36,37,51–54}.

In terms of dendritic function and synaptic plasticity, *Fmr1* KO mice have a higher threshold for spike timing-dependent plasticity in the prefrontal cortex⁵⁵, and changes in the input resistance of dendritic compartments, which can significantly impact dendritic summation and, thus, cellular excitability^{37,56–58}. In line with elevated dendritic excitability, higher single-spine glutamate currents and elevated dendritic gain (resulting in higher action potential output) are observed in somatosensory cortex layer 4 stellate cells of *Fmr1* KO mice⁵⁹. In addition, there are major FMRP-related abnormalities in neurotransmitter release across several types of neuron. For instance, glutamate release is elevated in the axon terminals of dorsal root ganglion neurons^{60,61}

Audiogenic seizures

Seizures that are triggered by acoustic stimulation.

UP states

One of the two preferred subthreshold membrane potentials of a neuron, characterized by a more depolarized state during which it is easier for a neuron to fire action potentials.

Feedforward inhibition

A ubiquitous unitary motif in the organization of neural circuits in which an excitatory neuron excites an inhibitory interneuron, which then in turn inhibits a downstream excitatory cell (or cells).

and at the hippocampal CA3–CA1 synapse during spike trains^{43,62,63}.

Several studies have also observed synaptic deficits in inhibitory interneurons, including reduced GABA release in the hippocampus of *Fmr1* KO mice^{44,64}, attributable in part to excessive presynaptic GABA_B receptor signalling in inhibitory presynaptic terminals⁴⁴. By contrast, Yang et al. report increased GABA release from basket cells in the cerebellum of *Fmr1* KO mice, resulting in reduced firing frequency among postsynaptic Purkinje neurons⁶⁵. Although contradictory at first glance, Purkinje neurons are inhibitory, and thus the circuit-level effects of these changes are similar — both reduce circuit inhibition and promote hyperexcitability. Similarly, in the amygdala, loss of FMRP causes a marked

reduction in the frequency and amplitude of inhibitory postsynaptic currents, reduced tonic inhibition and decreased GABA availability⁴⁸. In the subiculum, loss of FMRP leads to selective reduction of tonic inhibition, but not phasic inhibitory postsynaptic currents, suggesting that specific subtypes of GABA_ARs mediating tonic inhibitory currents are downregulated⁶⁶.

The roles of channelopathies in FXS

Overview

Most of the pathological changes in excitability associated with FXS can be attributed to ion channel dysfunction that occurs as a result of the loss of FMRP, which regulates multiple types of channel across various neuronal subcompartments (FIG. 1; TABLE 1). The specific functional consequences of FMRP loss include changes in action potential initiation and firing pattern (involving various K⁺ and Na⁺ channels), neurotransmitter release (involving Ca²⁺ and K⁺ channels) and dendritic function (involving K⁺, Ca²⁺ and HCN channels, as well as AMPA receptors (AMPARs), NMDA receptors (NMDARs) and GABA_ARs) (BOX 2; TABLE 2). In turn, these functional effects are likely part of the mechanisms underlying cognitive and behavioural hallmarks of FXS. In the following sections, we discuss recent advances in our understanding of channelopathy-based mechanisms of FXS pathophysiology and potential new therapeutic strategies stemming from our growing knowledge of FXS-related ion channel defects. Where applicable, we also review efforts to investigate potential therapeutic interventions that target particular channelopathies (TABLE 3).

Action potential initiation and firing

The FXS-related hyperexcitability noted at the behavioural and circuit levels is apparent in the lowered action potential threshold and elevated firing frequency characteristic of *Fmr1* KO animal models. These changes involve functional alterations to both K⁺ channels and Na⁺ channels.

The role of K⁺ channels. K⁺ channels crucially contribute to establishing the resting membrane potential, and setting action potential dynamics and firing patterns. FMRP regulates the translation of numerous K⁺ channels, as well as their activity and surface expression (FIG. 2).

FMRP directly regulates the expression of delayed rectifier K⁺ channel (Kv3.1) mRNA^{67,68}. The rapid voltage-dependent activation/deactivation characteristics of Kv3.1 facilitate high firing rates in cells that express these channels. For example, there is normally a gradient of Kv3.1 expression within the sound localization circuitry of the brainstem (the medial nucleus of the trapezoid body). However, when FMRP is absent, the normal gradient distribution of Kv3.1 is flattened and the levels of Kv3.1b protein are higher overall⁶⁹. Consequently, the high-threshold (Kv3.1-dependent) current is increased in the medial nucleus of the trapezoid body of *Fmr1* KO mice, leading to faster action potential repolarization and higher firing rates (that is, hyperexcitability)⁵³.

Table 1 | Mechanisms of FMRP regulation of ion channels


Channel/modulation	Direction of modulation by FMRP	Refs
Translational control		
Kv1.2	↑ or ↓	58,65,94
Kv3.1	↓	67,68
Kv4.2	↑ or ↓	94–96
Slack	↔ or ↓	72,94
BK	↑	157
Cav1.3	↑ or ↓	88,98
Cav2.1	↑	89,94
Cav2.3	↓	90,94
HCN	↑ or ↓	56,57,94,101
AMPA	↑ or ↓	59,83,103,104
NMDAR	↑ or ↓	59,110–112,115
GABA _A R	↓	64,118–124
Ion channel activity via FMRP–channel interactions		
Slack	↑	72
BK	↑	57,62,80
SK	↑ or ↓	51,86
Kv1.2	↑	65
Kv4	↓	91
Cav3	↓	91
Ion channel surface expression via FMRP–channel interactions		
Kv1.2	↑	65
Cav2.1	↑	60,89
Cav2.2	↓	60
HCN	↑ or ↓	101
AMPA	↑ or ↓	59,107
Second messenger pathways		
I _{NaP}	↓	52
Unidentified		
NKCC1	↓	144,145

↑ or ↓, FMRP increases or decreases channel function, respectively; ↔, no significant change in channel function. AMPAR, AMPA receptor; BK, large-conductance voltage and Ca²⁺-activated K⁺ channel; Cav, voltage-gated Ca²⁺ channel; FMRP, fragile X mental retardation protein; GABA_AR, GABA type A receptor; HCN, hyperpolarization-activated cyclic nucleotide-gated ion channel; I_{NaP}, voltage-gated Na⁺ channel carrying persistent Na⁺ current; Kv, voltage-gated K⁺ channel; NKCC1, Na⁺–K⁺–Cl[–] co-transporter; NMDAR, NMDA receptor; SK, small-conductance Ca²⁺-activated K⁺ channel.

As increased Kv3.1 channel expression contributes to impaired encoding and processing of auditory information in *Fmr1* KO mice⁶⁸, these channels are promising therapeutic targets. Indeed, the Kv3.1 channel modulator AUT2 normalizes the action potential firing rate in auditory brainstem neurons and restores the auditory brainstem response in vivo in *Fmr1* KO mice⁵³. Targeting Kv3.1 channels may have an even broader therapeutic potential to reduce sensory hypersensitivity across multiple modalities in FXS, as Kv3.1 channels are widely expressed in rapidly firing neurons throughout the nervous system⁷⁰. However, it remains to be determined whether loss of FMRP also increases excitability among these rapidly firing neurons in various brain regions in a Kv3.1-dependent manner.

Slack channels are widely expressed in the brain, including in the brainstem, cerebellum, prefrontal cortex and hippocampus. As a major component of the delayed

outward current, Slack channels are critical in regulating action potential firing patterns and temporal precision⁷¹. FMRP directly modulates Slack channel activity⁷². In a seminal study, Kaczmarek and colleagues show that the amino-terminal domain of FMRP interacts with the Slack channel carboxy terminus to increase the frequency of the channel opening (that is, gating) in a rapid and reversible manner^{72,73}. Through this protein–protein interaction, FMRP dynamically and precisely tunes Slack channel activity and, thus, neuronal firing. In the absence of FMRP, Slack currents are significantly reduced, thus increasing neuronal excitability and reducing temporal precision of spiking, as observed in the auditory brainstem of *Fmr1* KO mice⁷². Together with the aforementioned effects on Kv3.1 channels, the FMRP-related decrease in Slack currents likely contributes to auditory hypersensitivity in FXS.



Hyperextensibility

The ability of the finger joints to move beyond their normal range of motion.

Interestingly, an additional ‘non-conducting’ function for Slack channels in regulating neuronal firing has been reported in *Aplysia* bag cell neurons in which activation of Slack channels is linked to protein synthesis-dependent, prolonged changes in neuronal firing patterns⁷³. This function raises the possibility that Slack–FMRP interactions may link changes in neuronal firing to changes in protein translation, known to be disrupted in FXS.

Large conductance voltage and Ca²⁺-activated K⁺ (BK) channels are widely expressed throughout the brain, and in nearly every cellular compartment of neurons⁷⁴. Being both voltage and calcium activated, these channels play critical roles in regulating neuronal excitability, action potential duration, firing and neurotransmitter release⁷⁵. FMRP targets BK channels, regulating translation and function^{43,57,62,76–80}. Specifically, the N-terminal domain of FMRP interacts with the channel’s regulatory β4-subunit to increase the BK channel’s Ca²⁺ sensitivity and, thus, open probability^{43,62}. FMRP can also directly bind to the BK channel’s pore-forming α-subunit^{76,80} to modulate channel gating and increase BK currents⁸⁰. Indeed, studies of both *Fmr1* KO mice and stem cell-derived neurons from patients with FXS report that the loss of FMRP reduces BK channel activity, which in turn leads to a wide range of functional

consequences. For example, in hippocampal and cortical neurons these effects include increased firing, excessive action potential broadening, elevated presynaptic Ca²⁺ influx and increased glutamate release^{43,62,76,81}.

More recent studies support the idea that the loss of FMRP–BK channel interactions contributes to FXS pathophysiology. Particularly interesting is the discovery that a rare FMRP missense mutation (R138Q), which is associated with a partial clinical FXS phenotype (intellectual disability and seizures) in at least one human patient, impairs the protein’s translation-independent presynaptic functions, including its ability to interact with BK channels to regulate action potential duration and control glutamate release (that is, excitability)⁷⁶. In *Drosophila*, this mutation impairs the presynaptic-specific function of FMRP to control axonal elaboration in the neuromuscular junction⁷⁶. In mouse cortical neurons, although the R138Q mutation preserves FMRP’s canonical mRNA-binding and translational regulation functions — generally associated with (but not limited to) postsynaptic compartments — it impairs interactions with BK channels that ultimately control glutamate release⁷⁶. These results suggest a model in which the effects of R138Q mutation are caused by disruption of FMRP’s protein–protein interactions, including FMRP–BK channel interactions, which are important in regulating neuronal excitability and glutamate release, while retaining the translational regulation functions of FMRP.

Despite the compelling alignment of both clinical and preclinical data linking these specific FMRP functions to a specific subset of FXS phenotypes, the story is likely more complicated. Two other individuals with FXS who harbour the same mutation present with different clinical phenotypes: one (male) presents with a more extensive set of FXS features, including intellectual disability, attention deficit hyperactivity disorder, autism, seizures, craniofacial changes and hyperextensibility²; the other (unrelated female) presents with mild intellectual disability and attention deficits⁸². Data from a rodent model of FXS specific to the R138Q mutation indicate that at least some postsynaptic functions of FMRP are also impacted by this mutation; surface expression of AMPARs is increased, as is dendritic spine density, hippocampal long-term potentiation (LTP) is impaired and there are socio-cognitive deficits at the behavioural level⁸³. These data suggest that the R138Q mutation may disrupt FMRP interactions with other channels as well, resulting in both presynaptic and postsynaptic defects.

Upregulating BK channel activity may be a useful approach to normalize a range of excitability-associated phenotypes in FXS. Indeed, genetically upregulating BK channel activity normalizes multiple synaptic and circuit defects in an FXS mouse model, including action potential broadening, elevated glutamate release and epileptiform activity in the hippocampal circuit⁴³. Moreover, the BK channel opener BMS-204352 corrects numerous behavioural phenotypes in *Fmr1* KO mice, including hyperactivity, hypersensitivity to sensory stimuli, social defects, anxiety, deficient spatial memory, impaired nest building and excessive grooming^{57,77,84}. Together, these studies suggest that targeting BK channels may

Fig. 1 | Overview of channelopathies in FXS. a | Although fragile X syndrome (FXS) clinical manifestations are complex and vary considerably among individuals, most patients with FXS exhibit cognitive dysfunction (intellectual disabilities, learning deficits, language delay), social and behavioural problems (anxiety, autism spectrum disorders) and neurological deficits (seizures, abnormal sleep patterns), indicative of cellular and network hyperexcitability. **b** | Brain regions that are affected in FXS and discussed in this review (somatosensory cortex, prefrontal cortex, hippocampus, entorhinal cortex, amygdala, cerebellum) in a medial view (left panel, brainstem and cerebellum removed) and a lateral view (right panel). **c** | Cartoon representation of the basic unitary neural circuit showing increased circuit excitability and excitation/inhibition imbalance, a key feature of the circuit changes observed in FXS. **d** | Hyperexcitability defects observed in FXS can be attributed to channelopathy-caused functional abnormalities in action potential initiation and firing, neurotransmitter release and/or dendritic function, which may underlie various FXS phenotypes shown in panel **a** (right-turn arrow from panel **d** to panel **a**). Ion channels contributing to these excitability defects are listed in corresponding inserts. Insert 1: FXS-related hyperexcitability is apparent in elevated neuronal firing frequency. These changes involve functional alterations in both potassium channels and sodium channels, including Kv1.2, Kv3.1, Slack, BK, SK, I_{NaP} and I_{NaT}. Action potential traces in light-blue and blue represent normal and FXS conditions, respectively, indicating that loss of fragile X mental retardation protein (FMRP) increases the action potential firing frequency. Insert 2: transduction of neuronal firing into neurotransmitter release at presynaptic terminals is mediated by Ca²⁺ influx through the voltage-gated calcium channels (VGCCs). Cav2.1 and Cav2.2 channels are the predominant VGCCs supporting neurotransmitter release in central neurons. FMRP can also indirectly regulate neurotransmitter release by controlling the action potential peak and duration, which in turn determine the amplitude and duration of presynaptic calcium influx through VGCCs. This mechanism is mediated by a subset of voltage-gated K⁺ channels, including Kv1.2 and BK channels. Insert 3: dendritic excitability is governed, in large part, by ion channels, a number of which are dysregulated in the absence of FMRP, including HCN, Kv4, BK, Cav1, Cav2.3, Cav3, AMPAR, NMDAR, GABA_AR and NKCC1. Excitatory postsynaptic potential (EPSP) waveforms in light-blue and blue denote normal and FXS conditions, respectively, indicating that loss of FMRP enhances EPSP integration and, thus, increases dendritic excitability. AMPAR, AMPA receptor; BK, large-conductance voltage and Ca²⁺-activated K⁺ channel; Cav, voltage-gated Ca²⁺ channel; GABA_AR, GABA type A receptor; HCN, hyperpolarization-activated, cyclic nucleotide-gated ion channel; I_{NaP}, voltage-gated Na⁺ channel carrying persistent Na⁺ current; I_{NaT}, voltage-gated Na⁺ channel carrying transient Na⁺ current; Kv, voltage-gated K⁺ channel; NKCC1, Na⁺-K⁺-Cl⁻ co-transporter; NMDAR, NMDA receptor; SK, small-conductance Ca²⁺-activated K⁺ channel.

Box 2 | Mechanisms underlying excitability defects in fragile X syndrome models

Loss of fragile X mental retardation protein (FMRP) dysregulates a large number of ion channels. This, in turn, affects multiple aspects of neuronal excitability, including changes in the action potential initiation and firing rate, presynaptic vesicle release, dendritic properties and synaptic plasticity (TABLE 2).

- The combined activity of voltage-gated Na⁺ and K⁺ channels determines the action potential shape, firing rate and pattern. For example, channels that are active around threshold potentials, such as small-conductance Ca²⁺-activated K⁺ (SK) channels and Na⁺ channels carrying persistent Na⁺ current (I_{NaP}), contribute to action potential initiation. Na⁺ channels carrying transient Na⁺ current (I_{NaT}) determine the action potential rising speed and amplitude. Several families of voltage-gated K⁺ channels act in concert to determine action potential repolarization dynamics, and thus the action potential duration.
- Action potential firing patterns are transduced into synaptic vesicle release at synaptic terminals via activation of voltage-gated calcium channels (VGCCs), among which P/Q-type and N-type Ca²⁺ channels are the major source of Ca²⁺ for synaptic vesicle release in central neurons.
- Multiple channels act together to control dendritic excitability and input resistance, and thus spatial and temporal summation, including K⁺ channels, VGCCs and hyperpolarization-activated cyclic nucleotide-gated channels. Many of these channels are also involved in the initiation and maintenance of various forms of synaptic plasticity. Ligand-gated ion channels/ionotropic receptors (AMPA, NMDA and GABA_A receptors) function to directly evoke excitatory or inhibitory synaptic currents.
- Many channels are expressed in multiple cellular compartments and be activated by different factors, in cell type-specific and brain region-specific manners.

have therapeutic potential in alleviating numerous excitability-associated FXS phenotypes.

Kv1.2 channels are widely distributed across various cellular compartments of neurons, and play important roles in regulating intrinsic excitability and action potential initiation⁸⁵. In *Fmr1* KO mice, the Kv1-mediated current is downregulated in one population of layer 5 pyramidal cells of the medial prefrontal cortex (called long tract-projecting neurons), leading to increased excitability of these neurons⁵⁸. Interestingly, this defect appears to be cell type-specific, as it is not observed in the neighbouring intratelencephalic projecting pyramidal cells of the same brain region. Mechanistically, FMRP binds Kv1.2 channel mRNA, and interacts directly with the channel through protein–protein interactions to regulate channel activity and surface expression. Specifically, recent studies indicate that the N terminus of FMRP directly binds to a phosphorylated serine motif on the C terminus of Kv1.2 to form a dimer–dimer configuration in which two C-terminal strands of the same Kv1.2 channel bind to one FMRP dimer⁶⁵. This interaction enhances axonal trafficking, membrane expression and gating dynamics of Kv1.2 in axonal terminals of cerebellar basket cells, ultimately impacting presynaptic excitability and Ca²⁺ influx. Consequently, loss of FMRP–Kv1.2 interaction in *Fmr1* KO basket cells increases the duration and amplitude of action potentials, leading to enhanced presynaptic Ca²⁺ influx and excessive GABA release onto Purkinje neurons⁶⁵. As Purkinje neurons are inhibitory, the overall effect of these changes is to promote circuit hyperexcitability.

As Purkinje neurons are the sole output cells from the cerebellar cortex, the Kv1.2 channelopathy is likely to lead to abnormal cerebellar functions. Targeting Kv1.2 may thus help normalize cerebellar circuit hyperexcitability

and cerebellar-related abnormalities in FXS. Indeed, the therapeutic potential of one Kv1.2 agonist, docosahexaenoic acid, was recently tested in an FXS mouse model, where it was found to rectify the dysregulated cerebellar inhibition in vitro and to rescue acoustic startle reflex and social interaction phenotypes in vivo⁶⁵.

Voltage-independent K⁺ channels also play key roles in regulating neuronal excitability by modulating the resting membrane potential, action potential threshold and afterpotentials⁸⁵. Within the context of *Fmr1* KO mice, there is evidence of hypofunction of the SK channel, which is linked to neuronal hyperexcitability (lower action potential threshold, smaller medium afterhyperpolarization, increased firing rate and exaggerated synaptic gain) in CA3 pyramidal cells⁵¹. The SK current defect stems from the loss of FMRP interactions with the SK2 channel isoform, although channel expression is unaffected. This idea is further supported by the finding that all observed excitability defects in CA3 pyramidal cells of *Fmr1* KO mice are normalized by acute intracellular reintroduction of the N-terminal FMRP fragment (amino acids 1–298) or the genetic reintroduction of an even shorter N-terminal FMRP fragment (amino acids 1–234), both of which lack the KH2 domain and are thus incapable of translational regulation⁵¹. Interestingly, similar to other FXS-related channelopathies, the SK defects are cell type-specific. Within a single *Fmr1* KO animal, changes to the SK current in CA1 pyramidal cells mirror those apparent in CA3 cells: the SK current increases, as does the spike rate variability and medium afterhyperpolarization, but the action potential rate decreases⁸⁶. Similar cell type-specific changes are also reported for Kv1 (REF.⁵⁸) and HCN channels^{56–58} (TABLE 1).

The role of Na⁺ channels. In most neurons, the action potential initiation and rising phase are governed by voltage-gated Na⁺ channel availability and activation/inactivation dynamics. Na⁺ channels can produce two distinct currents: the fast transient Na⁺ current (I_{NaT}) and the non-inactivating persistent Na⁺ current (I_{NaP}). I_{NaP} is active at subthreshold voltages, and thus is critical for action potential initiation, whereas I_{NaT} underlies the action potential rising phase⁸⁵. Thus, disruption to either current is likely to impact neuronal excitability.

In *Fmr1* KO mice, I_{NaP} is abnormally increased in the entorhinal cortex layer 3 pyramidal cells, that is, neurons that project directly to the CA1 region. This upregulation of I_{NaP} leads to profound excitability defects, including lower action potential threshold and increased action potential firing⁵². Unlike many K⁺ channel defects, which are mediated by FMRP–channel interactions within individual neurons, I_{NaP}-mediated defects are not apparent in neurons isolated from their circuit. This indicates that the defects are not cell autonomous. Indeed, the enhanced I_{NaP} is caused by exaggerated activation of mGluR5 signalling, which in turn acts on Na⁺ channels through phospholipase C (PLC) and protein kinase C (PKC)⁵². This signalling mechanism requires circuit activity and is distinct from the well-established mGluR5 signalling cascade affecting local translation in FXS animal models. Thus, Na⁺ channel dysregulation is likely a major contributor to neuronal hyperexcitability

Intratelencephalic projecting pyramidal cells
Telencephalic pyramidal cells whose axons project to regions within the telencephalon.

in the FXS mouse model, at least in this subpopulation of cortical neurons.

Although the above study did not include direct measures of I_{NaT} , the observation of increased action potential rising speed, an I_{NaT} -dependent parameter, suggests that I_{NaT} is also increased in *Fmr1* KO neurons⁵². Indeed, direct evidence of increased I_{NaT} resulting in

larger and faster rising action potentials and a higher gain of somatic excitability is reported in layer 2/3 prefrontal cortex neurons of *Fmr1* KO mice⁵⁴. This study also finds that the observed excitability changes are accompanied by a large depolarizing shift in the activation of A-type K^+ channels. This shift is expected to decrease the action potential threshold, as is the case when I_{NaP} is higher. However, no such changes were observed⁵⁴, indicating that some form of compensatory changes may be involved.

Taken together, the data discussed here reflect a complex interplay of cell type-specific Na^+ and K^+ channelopathies caused by loss of FMRP. In nearly all cases, the deficits contribute to overall neuronal and circuit hyperexcitability. To elucidate further mechanistic detail will require careful consideration of cell type-specific effects, as well as the impact of compensatory changes.

Neurotransmitter release

The transduction of neuronal firing into neurotransmitter release at presynaptic terminals is mediated by Ca^{2+} influx through the voltage-gated calcium channels (VGCCs)⁸⁷. Interestingly, in FXS models, all five types of mammalian VGCC — P/Q (Cav2.1), N (Cav2.2), R (Cav2.3), L (Cav1) and T (Cav3) — are affected^{6,60,61,88–91} (FIG. 2; TABLE 2). N-type and P/Q-type channels are the predominant VGCCs supporting neurotransmitter release at most central synapses and are discussed here; those VGCC types that contribute to dendritic excitability changes in FXS are discussed in the next section.

N-type and P/Q-type VGCCs. The N-type VGCC (Cav2.2) plays a prominent role in neurotransmitter release at presynaptic terminals. It was also the first Ca^{2+} channel found to be directly modulated by FMRP through protein–protein interactions⁶⁰. The mechanism of this interaction is distinct from the known FMRP interactions with K^+ channels; in the case of the N-type VGCC, the FMRP C-terminal domain interacts with the N-type channel's synaptic targeting domain^{60,61} to suppress the channels' presynaptic localization and surface expression. Consequently, loss of FMRP increases N-type VGCC surface expression and glutamate release at presynaptic terminals of sensory neurons in the dorsal root ganglia^{60,61}.

The P/Q-type (Cav2.1) channel is also critical for action potential-evoked neurotransmitter release in many types of neuron. It is involved in various forms of synaptic plasticity as well as spatial learning and memory in mice⁹². In cortical neurons, overall levels of P/Q-type channels are unaltered by FMRP loss. However, we know that FMRP can bind to these channels to increase their surface expression^{60,89}; this is the opposite of the effect of FMRP interactions with N-type channels. Thus, loss of FMRP results in reduced surface expression of P/Q-type channels, whereas surface expression of N-type channels is simultaneously increased⁸⁹. Interestingly, it has been suggested that N-type and P/Q-type channels have channel type preferred slots in hippocampal synapses, which can be occupied by the competing channel type upon certain disease conditions⁹³. Thus, the loss of FMRP may contribute to synaptic transmission deficits

Table 2 | Mechanisms underlying excitability defects in fragile X syndrome models

Channel	Changes	Functional abnormality	Refs
Action potential initiation and firing pattern			
Kv3.1	↑	↑ Action potential repolarization speed and firing rate	53,68
Slack	↓	↑ Action potential duration and firing rate	73
BK	↓	↑ Action potential duration, ↓ fAHP	62
Kv1.2	↓	↑ Action potential duration	65
SK	↓	↓ Action potential threshold and mAHP, ↑ action potential firing rate	51
	↑	↑ mAHP, ↓ action potential firing rate	86
I_{NaP}	↑	↓ Action potential threshold, ↑ action potential firing rate	52
I_{NaT}	↑	↑ Action potential rising speed and amplitude ↑ Action potential firing rate, ↓ action potential duration	54
Neurotransmitter release			
Cav2.1	↓	↓ Ca^{2+} influx and vesicle release	89
Cav2.2	↑	↑ Ca^{2+} influx and vesicle release	60,61
BK	↓	↑ Ca^{2+} influx and vesicle release	62
Kv1.2	↓	↑ Ca^{2+} influx and vesicle release	65
Dendritic function			
Kv4	↑	↑ Threshold for LTP, lack of TBS-induced LTP	91,96
Cav3	↑	↑ Ca^{2+} influx	88
BK	↓	↑ Dendritic excitability, ↑ sensory sensitivity, ↑ dendritic spines	57,77
Cav1	↓	↑ Threshold for tLTP	55,98
	↑	↑ Progenitor differentiation to glutamate-responsive cells	88
Cav2.3	↑	↑ Ca^{2+} influx	90
HCN	↓	↑ Input resistance and summation	56,101
	↑	↓ Input resistance and summation	57,59,101
AMPA	↓	↓ LTP and ↑ LTD	103,104
	↑	↓ LTP, ↑ AMPAR current ↑ Silent dendritic spines	59,83
NMDAR	↓	↓ NMDAR currents	112,115
	↑	↑ NMDAR mEPSC frequency	59
GABA _A R	↓	↓ Inhibition	64,119,120
NKCC1	↑	Delayed GABA _A R polarity switch, delayed maturation of glutamatergic synapses	144,145

↑, increase; ↓, decrease. AMPAR, AMPA receptor; BK, large-conductance voltage and Ca^{2+} -activated K^+ channel; Cav, voltage-gated Ca^{2+} channel; fAHP, fast afterhyperpolarization; GABA_AR, GABA type A receptor; HCN, hyperpolarization-activated cyclic nucleotide-gated ion channel; I_{NaP} , voltage-gated Na^+ channel carrying persistent Na^+ current; I_{NaT} , voltage-gated Na^+ channel carrying transient Na^+ current; Kv, voltage-gated K^+ channel; LTD, long-term depression; LTP, long-term potentiation; mAHP, medium afterhyperpolarization; mEPSC, miniature excitatory postsynaptic current; NKCC1, $Na^+-K^+-Cl^-$ co-transporter; NMDAR, NMDA receptor; SK, small-conductance Ca^{2+} -activated K^+ channel; TBS, theta-burst stimulation; tLTP, spike-timing-dependent long-term potentiation.

Table 3 | Manipulations that rescue cellular, circuit and behavioural phenotypes in fragile X syndrome models

Target	Rescue strategy	Behavioural phenotypes normalized	Refs
Kv1.2	Oral administration of Kv1.2 agonist DHA	Acoustic startle reflex and social interaction	65
Kv3.1	Kv3.1-positive modulator AUT2	MNTB neurons firing rate Auditory brain response	53
Kv4	Kv4 blocker heteropodatoxin	TBS-induced LTP in hippocampus	96
Slack	FMRP ₁₋₂₉₈	Slack open probability	72,73
BK	Intracellular application of FMRP ₁₋₂₉₈ Genetic upregulation of BK activity by ablation of BK β 4 subunit	Action potential duration, BK open probability, glutamate release Short-term plasticity Epileptiform activity	43,62,76
	Intraperitoneal injection of BK channel opener BMS-204352	Acoustic startle reflex, locomotor activity, nest building, grooming, social interactions, anxiety and spatial memory	57,77,84
SK	Intracellular administration of FMRP ₁₋₂₉₈ , genetic reintroduction of FMRP ₁₋₂₃₄ or SK channel opener 1-EBIO or NS309	Action potential threshold, mAHP and action potential firing rate MF CA3 input–output transmission	51
NMDAR	Bath application of NMDAR co-agonists glycine or D-serine	NMDAR-dependent LTP in dentate gyrus	112
GABA _A R	Intraperitoneal injection of GABA _A R agonist ganaxolone, acamprosate or metadoxine	UP states, locomotor activity, anxiety, marble-burying behaviour and sensory hyperresponsiveness	126,130
NKCC1	Intraperitoneal injection of NKCC1 inhibitor bumetanide	GABA _A R reversal potential of L4 somatosensory neurons Excitatory synapse development LTP in somatosensory cortex Whisker-evoked responses in the cortex	145
FMRP loss	Intravenous injection of FMRP _{297-tat}	Cav3 and Kv4 currents Cerebellar MF granule cell LTP Protein levels (APP, α CaMKII and PSD95), locomotor activity	91

α CaMKII, α -Ca²⁺/calmodulin-dependent protein kinase II; AUT2, 4-(³oxy)-2-(1-methylethyl) benzonitrile; BK, large-conductance voltage and Ca²⁺-activated K⁺ channel; Cav, voltage-activated Ca²⁺ channel; DHA, docosahexaenoic acid; FMRP, fragile X mental retardation protein; GABA_AR, GABA type A receptor; Kv, voltage-gate K⁺ channel; LTP, long-term potentiation; mAHP, medium afterhyperpolarization; MF, mossy fibre; NS309, 3-oxime-6,7-dichloro-1H-indole-2,3-dione; MNTB, medial nucleus of the trapezoid body; NKCC1, Na⁺-K⁺-Cl⁻ co-transporter; NMDAR, NMDA receptor; PSD, postsynaptic density; SK, small-conductance Ca²⁺-activated K⁺ channel; TBS, theta-burst stimulation.

by creating an imbalance between the surface levels of N-type and P/Q-type channels, which differentially contribute to the efficiency of neurotransmitter release and synaptic plasticity⁹³.

Indirect modulation of calcium influx. In addition to controlling presynaptic surface expression of VGCCs, FMRP can also indirectly regulate neurotransmitter release by controlling the action potential duration (which, in turn, determines the duration of presynaptic calcium influx through VGCCs). This mechanism is mediated by a subset of voltage-gated K⁺ channels that regulate action potential duration, and has major implications for glutamate and GABA release, both of which are significantly impacted in *Fmr1* KO mice. As discussed above, reduced BK channel activity in hippocampal and cortical excitatory neurons of *Fmr1* KO mice leads to extensive action potential broadening. This, in turn, elevates presynaptic calcium influx and glutamate release⁶². Similarly, the increased action potential duration apparent in cerebellar basket cells (secondary to reduced Kv1.2 channel activity) leads

to excessive GABA release⁶⁵. VGCC–K⁺ channel activity interdependence is often reciprocal; for example, VGCCs are the main source of Ca²⁺ to activate BK channels, whereas BK channels can physically couple to pore-forming α -subunits of L-type, P/Q-type and N-type VGCCs⁷⁴. This reciprocal interdependence is present to various extents across different types of central neuron. Thus, it likely contributes to neuronal hyperexcitability within the context of FXS.

Dendritic function


There are numerous reports of disrupted dendritic function in FXS models, including changes in excitability, gain, integration and multiple forms of long-term synaptic plasticity localized to the dendritic compartment^{37,55–59}. These functions are governed, in large part, by ion channels, a number of which are dysregulated in the absence of FMRP (BOX 2; TABLE 2).

K⁺ channels. The Kv4.2 channel regulates hippocampal and neocortical dendritic excitability and synaptic plasticity. FMRP can bind Kv4.2 mRNA and regulate


its translation^{94–96}. FMRP can also directly interact with and regulate Kv4 activity. Specifically, reduced A-type K⁺ currents (carried by Kv4 channels) in hippocampal pyramidal cells of *Fmr1* KO mice are associated with

hyperpolarizing shifts in channel activation and inactivation kinetics⁹⁷, suggesting changes to channel gating properties. Moreover, FMRP constitutively binds to the complex of Kv4 and Cav3 channels in cerebellar


a FMRP directly regulates the gating of ion channels



b FMRP directly regulates the translation of ion channels



c FMRP regulates trafficking and surface expression of ion channels



d FMRP regulates channel activity via second messenger pathway





Fig. 2 | FMRP controls ion channel functions through multiple mechanisms. Fragile X mental retardation protein (FMRP) regulates channel functions by four major mechanisms. **a** | FMRP regulates ion channel gating. By interacting directly with the pore-forming subunit (1) and/or with the regulatory subunit (2) of ion channels, FMRP modulates the function of the pore-forming subunit and, thus, regulates neuronal excitability and neurotransmitter release. Ion channels regulated by FMRP through this mechanism include Slack, BK, SK, Kv1.2, Kv4.3 and Cav3. **b** | By binding to mRNA of ion channels, FMRP regulates ion channel translation and, thus, modulates neural excitability. Ion channels regulated by FMRP through this mechanism include Slack, BK, Kv1.2, Kv3.1, Kv4.2, Cav1.3, Cav2.1, Cav2.3, HCN, AMPAR, NMDAR and GABA_AR. **c** | By binding to ion channels, FMRP modulates ion channel trafficking and surface expression. Ion channels regulated by FMRP through this mechanism include Kv1.2, Cav2.1, Cav2.2, HCN and AMPAR. **d** | FMRP controls ion channel activity via second messenger pathways. By modulating the mGluR5–PKC–PLC pathway, FMRP modulates I_{NaP} and, thus, regulates the action potential threshold and excitability. Note that the same channel can be modulated via multiple mechanisms. Also, the direction of changes, extent and mechanism of channel modulation by FMRP is often brain region, cell type and even subcellular compartment-specific. AMPAR, AMPA receptor; BK, large-conductance voltage and Ca²⁺-activated K⁺ channel; Cav, voltage-gated Ca²⁺ channel; GABA_AR, GABA type A receptor; HCN, hyperpolarization-activated, cyclic nucleotide-gated ion channel; I_{NaP}, voltage-gated Na⁺ channel carrying persistent Na⁺ current; Kv, voltage-gated K⁺ channel; mGluR5, metabotropic glutamate receptor subtype 5; NMDAR, NMDA receptor; PKC, protein kinase C; PLC, phospholipase C; SK, small-conductance Ca²⁺-activated K⁺ channel.

granule cells to modulate activity of both channels⁹¹. In both cases, FMRP decreases channel currents primarily through a strong hyperpolarizing shift in inactivation kinetics, whereas channel density is unchanged⁹¹. The Cav3–Kv4–FMRP interaction has important functional consequences within the context of FXS. In *Fmr1* KO mice, the theta burst-induced form of LTP is absent in mossy fibre–granule cell synapses of the cerebellar cortex, a change that is attributed to increased Kv4 current⁹¹. Significantly, acute intracellular administration of the N-terminal FMRP fragment (amino acids 1–297) is sufficient to restore LTP defects; it directly modulates Cav3–Kv4 channel complex activity in the absence of translational changes⁹¹.

The fact that FMRP directly modulates Cav3–Kv4 complex activity raises the possibility that this interaction can be targeted as a therapeutic strategy. When the N-terminal fragment of FMRP is modified to facilitate blood–brain barrier crossing (conjugation to *tat*; FMRP₂₉₇-*tat*) and infused into *Fmr1* KO mice, it rapidly improves multiple functions at the cellular and behavioural levels, including restoration of Cav3–Kv4 complex activity, rescue of cerebellar mossy fibre LTP and normalization of hyperactivity in the open field test⁹¹. Interestingly, FMRP₂₉₇-*tat* also restores levels of several selected proteins (PSD95, CamKII) for at least 24 h. It remains unclear whether the observed changes in synaptic protein levels are a cause or a consequence of normalized LTP, as the FMRP₂₉₇ fragment lacks the ability to associate with polyribosomes and regulate translation. Additionally, there are still no data directly linking improvements in hyperactivity *in vivo* with restored Cav3–Kv4 complex function or the normalization of mossy fibre LTP. Understanding the mechanisms underlying FMRP₂₉₇-*tat* treatment is important because FMRP₂₉₇-*tat* is likely taken up by a wide range of excitatory and inhibitory neurons throughout the brain, including the cerebellum but also the cortex, hippocampus and other brain areas⁹¹. However, regardless of the precise mechanisms, a *tat*-conjugate approach is a promising strategy through which to reintroduce a combination of different FMRP segments containing various functional domains, thus wielding broad power to address FXS channelopathies.

In addition to their prominent presynaptic roles in controlling action potential duration and glutamate release, BK channels are also localized to dendrites and regulate dendritic excitability. In *Fmr1* KO mice, BK channel activity is reduced in dendrites of neocortical neurons, leading to exaggerated Ca²⁺ influx accompanying back-propagating action potentials and reduced dendritic spike threshold⁵⁷. The BK channel opener BMS-204352 rescues a wide range of behavioural phenotypes in these mice, which likely reflects the effect of normalizing both presynaptic and postsynaptic functions^{57,77,84}.

Calcium channels. In addition to the Cav3 (T-type) VGCC discussed above, a large proportion of depolarization-induced Ca²⁺ influx in dendrites is mediated by L-type (Cav1) VGCCs. The L-type channels regulate dendritic excitability, gene expression, synaptic plasticity, and

neural differentiation and migration⁸⁷. Cav1.3 mRNA is an FMRP target; channel expression is downregulated in the frontal cortex and cerebellum of *Fmr1* KO mice⁹⁸. In the dendritic spines of prefrontal cortex layer 2/3 neurons from *Fmr1* KO mice, the reduced expression of L-type channels is linked with defects in spike timing-dependent plasticity⁵⁵. Interestingly, in both human patients with FXS and mouse models, Ca²⁺ influx through L-type VGCCs is increased in neural progenitors derived from stem cells⁸⁸. Specifically, the ratio of L-type to T-type channels increases, leading to enhanced progenitor differentiation to glutamate-responsive cells. These findings suggest that there are significant implications of upregulated L-type channel function on differentiation, migration and fate determination in neural progenitor cells within the context of FXS⁸⁸.

The R-type calcium current is carried by Cav2.3, whose mRNA is also targeted by FMRP⁹⁴. This channel regulates burst-firing and afterdepolarization in dendrites, and its inhibition disrupts a form of mGluR-dependent long-term depression⁸⁷. Consistent with profound alterations in dendritic excitability and calcium spiking in neurons lacking FMRP, Cav2.3 expression and the R-type Ca²⁺ current are increased in brain synaptosomes and hippocampal cultured neurons from *Fmr1* KO mice⁹⁰. Moreover, loss of FMRP occludes mGluR-dependent Cav2.3 upregulation⁹⁰. We do not yet completely understand how these defects contribute to altered dendritic excitability in FXS models, as other factors are also involved in modulating excitability following mGluR stimulation, including the downregulation of several K⁺ channels⁹⁹.

HCN channels. HCN channels are active at rest, and therefore play a crucial role in controlling the resting membrane potential, input resistance and, thus, dendritic excitability¹⁰⁰. They are prominently expressed in the soma and dendrites of excitatory neurons, following an expression gradient that increases towards more distal regions to regulate the integration of synaptic events occurring at different dendritic locations. Numerous cell type-specific alterations in HCN channels are observed in FXS models. For example, in CA1 pyramidal cells of *Fmr1* KO mice, HCN1-subunit expression and dendritic HCN currents are elevated. This, in turn, decreases input resistance, reduces temporal summation and increases membrane resonance frequency⁵⁶. By contrast, in both layer 5 pyramidal cells of the somatosensory cortex and layer 4 stellate cells in these mice, HCN1 subunit expression and HCN current are decreased, leading to opposite changes in excitability, that is, increased dendritic gain^{57,59}. Mechanistically, FMRP bidirectionally regulates HCN channels via a protein–protein interaction mechanism in dendrites of hippocampal CA1 pyramidal cells and prefrontal cortex neurons¹⁰¹. FMRP associates with the HCN–TRIP8b complex to downregulate (in the hippocampus) or upregulate (in the prefrontal cortex) the number of functional dendritic HCN channels. This previously unrecognized mechanism expands the repertoire of modulatory mechanisms by which FMRP regulates ion channel functions and excitability (FIG. 2), in opposite directions depending on

the cellular milieu. If this type of regulation is observed more broadly in future studies, it may explain many cell type-specific changes in channel expression/activity in neurons lacking FMRP.

Ligand-gated ion channels. The ligand-gated ion channels are a group of postsynaptic neurotransmitter receptors, also known as ionotropic receptors. There are three major ionotropic receptors involved in FXS: AMPARs, NMDARs and GABA_ARs. The AMPARs and NMDARs are non-selective cation channels, whereas GABA_AR is a Cl⁻ channel. In addition to these channels, we discuss the impact of FMRP loss on the chloride transporters that maintain intracellular Cl⁻ ion homeostasis, as these transporters determine the GABA_AR polarity switch early in development involved in synaptogenesis and synapse maturation.

AMPA receptors mediate fast excitatory synaptic transmission in the brain. Altering the number of postsynaptic AMPARs is a fundamental mechanism of activity-dependent plasticity at excitatory synapses, including some forms of LTP and long-term depression. Local protein synthesis in dendrites is required for stable expression of LTP and long-term depression, and there is now evidence that these newly expressed proteins are regulated by specific RNA-binding proteins, including FMRP^{102–107}. Thus, FMRP may indirectly regulate synaptic plasticity through AMPAR-dependent functions^{59,83,102–107}. In *Fmr1* KO mice, expression of the AMPAR subunit GluA1 is decreased in the cortex (but not in the hippocampus or cerebellum¹⁰³), as is LTP^{103,104}. AMPARs also show brain region/cell type-specific defects in FXS models. Specifically, in the hippocampus, FMRP promotes GluA1 surface expression in adult-born granule cells of the dentate gyrus, but has no effect on total GluA1 protein levels^{106,107}. Consequently, loss of FMRP decreases surface expression of GluA1, reduces GluA1-mediated AMPA currents and delays dendritic maturation. By contrast, layer 4 stellate cells of the primary somatosensory cortex in *Fmr1* KO mice show elevated single-spine excitation with normal spine morphology, in part owing to increased AMPAR currents⁵⁹. Consistent with this, studies of a new FXS mouse model (point missense mutation R138Q in FMRP) reveal an increase in both total and surface expression of AMPAR subunits GluA1 and GluA2, decreased thickness of postsynaptic density and reduced LTP⁸³.

The evidence presented above raises the possibility that positive allosteric modulators of AMPARs could be useful for restoring some of the synaptic deficits associated with FXS. However, a double-blind clinical trial of one such compound, CX516, did not show significant improvements in cognition, language or attention/executive function in individuals with FXS¹⁰⁸. AMPARs also show brain region/cell type-specific defects in FXS models. Thus, globally targeting AMPARs is unlikely to be effective.

NMDARs are involved in synaptic transmission, plasticity and experience-dependent synaptic refinement during development. FMRP regulates transport and stabilization of NMDAR subunits GluN1, GluN2B (REF.¹⁰⁹) and GluN2A (REF.¹¹⁰). In the dentate gyrus of

Fmr1 KO mice, NMDAR currents are decreased and LTP is reduced¹¹¹. The reduction in NMDAR-dependent synaptic plasticity in this region is accompanied by lower levels of GluN1, GluN2A and GluN2B subunits. Indeed, the NMDAR co-agonists glycine and D-serine can restore NMDAR-dependent LTP in these mice to wild-type levels^{112,113}. At the behavioural level, NMDAR hypofunction is also linked to impaired context discrimination in adult *Fmr1* KO mice¹¹⁴. Most recently, Yau et al. found that lower NMDAR currents in the dentate gyrus of *Fmr1* KO mice are associated with a significant decrease in dendritic complexity (that is, reduced dendritic length and number of intersections)¹¹⁵. Yet, again, evidence points to cell type-specific changes in NMDAR levels and functions as a result of FMRP loss. NMDAR signalling is elevated in stellate cells of somatosensory cortex layer 4, and dendritic morphology is normal⁵⁹. In these cells, the increase in dendritic gain and enhanced summation appear to be caused by a threefold increase in the number of polysynaptic spines and an increase in intrinsic excitability. Interestingly, although the loss of FMRP causes abnormal synaptogenesis, there is little correlation between spine structure and function, at least at the age of the animals used in this study⁵⁹.

Fast inhibitory synaptic neurotransmission in the brain is mostly mediated by GABA and its ionotropic target, GABA_ARs¹¹⁶. The GABA_AR is a pentameric ion channel that is selectively permeable to Cl⁻ ions. Animal models of FXS show abnormalities in GABA_AR expression and function, as do human patients with FXS (for a review see REF.¹¹⁷). Kooy and colleagues initially found decreased expression of GABA_AR δ -subunit mRNA in *Fmr1* KO mice¹¹⁸. Further studies from multiple groups found that the protein levels of more than half of the GABA_AR subunits (including $\alpha 1$ – $\alpha 4$, $\beta 1$ – $\beta 3$, $\gamma 1$, $\gamma 2$ and δ) are lower in FXS mouse models^{48,64,119–124} and throughout the brain of patients with FXS¹²⁵. In addition, the amount of GABA itself is also lower across multiple brain regions in FXS mouse models^{126,127}. Such hypofunction of the GABAergic system is likely to cause profound circuit hyperexcitability. Indeed, Morin-Parent et al. demonstrate that reduced GABA_AR function causes impaired short-interval intracortical inhibition, which contributes to cortical hyperexcitability in individuals with FXS⁹.

Given the critical role of the GABAergic system in network excitability, GABA_AR agonists have the potential to ameliorate excitability-associated deficits in FXS^{128,129}. The GABA_AR agonists acamprosate, ganaxolone and metadoxine can improve multiple defects in *Fmr1* KO models, including neuromuscular junction overgrowth and locomotor defects¹³⁰, prolonged cortical UP state and anxiety¹³¹, and marble-burying behaviour and sensory hyperresponsiveness¹²⁶. However, when these compounds were tested in clinical trials of individuals with FXS, there were no significant improvements in outcome measures^{132–135}. Another strategy is to target metabotropic GABA_B receptors to alleviate FXS deficits by normalizing the GABAergic system. However, again, although the GABA_B receptor agonist baclofen restores cognitive and behavioural deficits in animal models^{136–139}, it did not impact primary outcome

Critical period

A time period during early postnatal life when the development and maturation of functional properties of the brain is strongly dependent on experiences or environmental influences.

measures in clinical trials^{140,141}. These results highlight the limitations of targeting a single aspect of excitability defects in FXS. Ultimately, the most effective treatment strategies are likely to be multifactorial.

Chloride transporters. In addition to wielding fine control over circuit excitability, GABAergic transmission plays a critical trophic role in cortical development through its early depolarizing action. During the first few postnatal weeks (the critical period) in rodents, activating GABA_AR depolarizes neurons, increasing their excitability and promoting Ca²⁺ entry¹⁴². This in turn regulates cell migration, proliferation and synaptogenesis. The early depolarizing effect of GABA results from a transient high intracellular Cl⁻ concentration that is only present early in development and is determined by the expression pattern of two Cl⁻ co-transporters: Na⁺-K⁺-Cl⁻ co-transporter (NKCC1) and K⁺-Cl⁻ co-transporter (KCC2). NKCC1, which transports Cl⁻ into neurons, is expressed at high levels early after birth, whereas the levels of KCC2, which extrudes Cl⁻ from neurons, gradually increase over the course of development¹⁴³. In the FXS mouse model, NKCC1 expression stays high through the end of the critical period, thus delaying the GABA_AR polarity switch and disrupting the normal trophic function of GABA^{144–146}.

Systemic administration of bumetanide to inhibit NKCC1 during the critical period rectifies the intracellular Cl⁻ imbalance in layer 4 somatosensory cortex neurons and corrects the development of thalamocortical excitatory synapses in *Fmr1* KO mice¹⁴⁵. Inhibiting NKCC1 during early development also leads to broad remodelling of the proteome in the barrel cortex, and restores adult tactile response maps in *Fmr1* KO mice¹⁴⁵. These findings provide a rationale for considering NKCC1 as a novel therapeutic target in FXS.

Caveats of targeting channelopathies

As we have presented above, channelopathies play wide and varied roles in FXS pathophysiology. This makes ion channel-targeting therapies of particular interest. Indeed, multiple ion channel modulators show promise based on their ability to normalize cellular-level, circuit-level and behaviour-level abnormalities in FXS animal models (TABLE 3). We note above many cases in which specific ion channel-targeting therapies have already been tested in both animals and human patients. However, in most cases, clinical trials fail to show efficacy. In fact, recent studies emphasize that loss of FMRP can have diverse effects on the same ion channel depending on the brain region, cell type or even subcellular compartment^{56,58,97}. This will make targeting any given ion channel for therapeutic intervention in FXS particularly challenging. Recent modelling studies also indicate that many cellular and synaptic pathologies in *Fmr1* KO mice are antagonistic at the circuit level, and hence may be compensatory to the primary pathology³⁷. Thus, although there has been major progress towards identifying the molecular dysfunctions at synaptic and cellular levels, we need to better understand the overall effects of various channelopathies on circuit functions to design more effective therapeutic strategies. Moreover, because

no single channelopathy can account for all, or even most, of the defects in FXS, a combinatory approach is almost certainly necessary. Alternatively, a strategy that targets the primary causes of ion channel dysfunctions (such as loss of interactions with, or translational regulation by, FMRP) might prove more efficient. For example, a *tat*-conjugate approach to reintroduce the N-terminal FMRP fragment via intravenous injection restores ion channel and synaptic functions in at least part of the brain, as well as locomotion activity at the behavioural level in *Fmr1* KO mice⁹¹. Finally, a role for astrocytes in modulating neuronal excitability and plasticity in FXS is beginning to emerge^{147–149}. This may represent another potential target through which to normalize excitability deficits in FXS.

Implications for ASD

FXS is one of the many causes of ASD and has comorbidities with other genetic causes and also with idiopathic ASD. FXS and FMRP loss-independent ASD, although genetically distinct, share significant clinical phenotypes. Indeed, their similarities suggest some level of common pathophysiology, including similar ion channel-based deficits¹⁵⁰. There are multiple types of ion channel and transporter that are affected, in similar ways, in both FXS and FMRP loss-independent ASD¹⁵¹, including Kv4.2 (REFS^{152,153}), BK channels¹⁵⁴, Na⁺ channels¹⁵⁵, Ca²⁺ (L-type, R-type and T-type) channels, HCN1 (REF.¹⁵⁶), GABA_AR and NKCC1 (REF.¹⁵¹). Moreover, channelopathies responsible for hyperexcitability of somatosensory neurons are part of the core developmental pathology in ASD models, leading to region-specific brain abnormalities during the critical period¹⁵⁶. Peripherally restricted GABA_AR agonists, which reduce hyperexcitability within peripheral sensory circuits, improve numerous ASD-associated behaviours in mouse models, including tactile over-reactivity, anxiety-like behaviours and certain social impairments¹⁵⁶. Together, these findings indicate that what we learn about the role of channelopathies in FXS pathogenesis is likely to have important implications for ASD stemming from other causes.

Concluding remarks

We now understand that FMRP wields control over neuronal and circuit excitability by regulating ion channels (FIG. 1; TABLES 1 and 2). Indeed, FMRP modulates the physiological functions of many different types of ion channel, each of which contributes uniquely to controlling intrinsic excitability, action potential properties, firing patterns, synaptic transmission, synaptic plasticity and dendritic integration. FMRP can regulate ion channel function via protein–protein interactions with pore-forming or regulatory subunits, or channel expression, and some channels are regulated via both mechanisms (FIG. 2). FMRP can also indirectly modulate channel activity through second messenger pathways. The various mechanisms through which FMRP regulates channel function may be brain region-specific, cell type-specific or even subcellular compartment-specific. Given that direct FMRP–channel interactions are rapid and reversible, this mechanism means that ion channels can be precisely and dynamically tuned, which is critical

for normal excitability, synaptic plasticity and information processing, and, ultimately, normal behavioural and cognitive functions. Consequently, loss of FMRP, as occurs in FXS, triggers a series of channelopathies that contribute to circuit hyperexcitability-related abnormalities, which in turn underlie core symptoms of FXS.

Focusing on the role of channelopathies in such neuronal and circuit-level defects will be crucial in understanding the mechanistic basis of FXS pathophysiology and in designing novel therapeutic strategies.

Published online 7 April 2021

1. Penagarikano, O., Mulle, J. G. & Warren, S. T. The pathophysiology of fragile X syndrome. *Annu. Rev. Genomics Hum. Genet.* **8**, 109–129 (2007).
2. Sitzmann, A. F., Hagelstrom, R. T., Tassone, F., Hagerman, R. J. & Butler, M. G. Rare FMR1 gene mutations causing fragile X syndrome: a review. *Am. J. Med. Genet. A* **176**, 11–18 (2018).
3. Contractor, A., Klyachko, V. A. & Portera-Cailliau, C. Altered neuronal circuit excitability fragile X syndrome. *Neuron* **87**, 699–715 (2015).
4. Devys, D., Lutz, Y., Rouyer, N., Bellocq, J. P. & Mandel, J. L. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. *Nat. Genet.* **4**, 335–340 (1993).
5. Brager, D. H. & Johnston, D. Channelopathies and dendritic dysfunction in fragile X syndrome. *Brain Res. Bull.* **103**, 11–17 (2014).
6. Ferron, L. Fragile X mental retardation protein controls ion channel expression and activity. *J. Physiol.* **594**, 5861–5867 (2016).
7. Salcedo-Arellano, M. J., Hagerman, R. J. & Martinez-Cerdeno, V. Fragile X syndrome: clinical presentation, pathology and treatment. *Cac. Med. Mex.* **156**, 60–66 (2020).
8. Nelson, S. B. & Valakh, V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. *Neuron* **87**, 684–698 (2015).
9. Morin-Parent, F., Champigny, C., Lacroix, A., Corbin, F. & Lepage, J. F. Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome. *Transl Psychiatry* **9**, 312 (2019).
10. Berry-Kravis, E. Epilepsy in fragile X syndrome. *Dev. Med. Child Neurol.* **44**, 724–728 (2002).
11. Sabaratnam, M., Vroegop, P. G. & Gangadharan, S. K. Epilepsy and EEG findings in 18 males with fragile X syndrome. *Seizure* **10**, 60–63 (2001).
12. Miller, L. J. et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. *Am. J. Med. Genet.* **83**, 268–279 (1999).
13. Merenstein, S. A. et al. Molecular–clinical correlations in males with an expanded FMR1 mutation. *Am. J. Med. Genet.* **64**, 388–394 (1996).
14. Kronk, R. et al. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. *Sleep* **33**, 679–687 (2010).
15. Carotenuto, M. et al. Polysomnographic findings in fragile X syndrome children with EEG abnormalities. *Behav. Neurol.* **2019**, 5202808 (2019).
16. Scharf, S. S., Gasparini, F., Spooen, W. & Lindemann, L. in *Fragile X Syndrome: From Genetics to Targeted Treatment* (eds Willemsen, R. & Kooy, R. F.) 363–399 (Elsevier, 2017).
17. Chen, L. & Toth, M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. *Neuroscience* **103**, 1043–1050 (2001).
18. Musumeci, S. A. et al. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. *Epilepsia* **41**, 19–23 (2000).
19. Yan, Q. J., Rammal, M., Tranfaglia, M. & Bauchwitz, R. P. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology* **49**, 1053–1066 (2005).
20. Osterweil, E. K. et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. *Neuron* **77**, 243–250 (2013).
21. Curia, G., Gualtieri, F., Bartolomeo, R., Vezzali, R. & Biagini, G. Resilience to audiogenic seizures is associated with p-ERK1/2 dephosphorylation in the subiculum of Fmr1 knockout mice. *Front. Cell Neurosci.* **7**, 46 (2013).
22. Gross, C. et al. Selective role of the catalytic PI3K subunit p110 β in impaired higher order cognition in fragile X syndrome. *Cell Rep.* **11**, 681–688 (2015).
23. Busquets-Garcia, A. et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. *Nat. Med.* **19**, 603–607 (2013).
24. Rotschafer, S. & Razak, K. Altered auditory processing in a mouse model of fragile X syndrome. *Brain Res.* **1506**, 12–24 (2013).
25. He, C. X. et al. Tactile defensiveness and impaired adaptation of neuronal activity in the Fmr1 knock-out mouse model of autism. *J. Neurosci.* **37**, 6475–6487 (2017).
26. Frankland, P. W. et al. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. *Mol. Psychiatry* **9**, 417–425 (2004).
27. Dansie, L. E. et al. Long-lasting effects of minocycline on behavior in young but not adult fragile X mice. *Neuroscience* **246**, 186–198 (2013).
28. Oddi, D. et al. Early social enrichment rescues adult behavioral and brain abnormalities in a mouse model of fragile X syndrome. *Neuropharmacology* **40**, 1113–1122 (2015).
29. Heulens, I., D’Hulst, C., Van Dam, D., De Deyn, P. P. & Kooy, R. F. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. *Behav. Brain Res.* **229**, 244–249 (2012).
30. Heard, T. T. et al. EEG abnormalities and seizures in genetically diagnosed fragile X syndrome. *Int. J. Dev. Neurosci.* **38**, 155–160 (2014).
31. Knoth, I. S., Vannasing, P., Major, P., Michaud, J. L. & Lippe, S. Alterations of visual and auditory evoked potentials in fragile X syndrome. *Int. J. Dev. Neurosci.* **36**, 90–97 (2014).
32. Castren, M., Paakkonen, A., Tarkka, I. M., Ryyanen, M. & Partanen, J. Augmentation of auditory N1 in children with fragile X syndrome. *Brain Topogr.* **15**, 165–171 (2003).
33. Gibson, J. R., Bartley, A. F., Hays, S. A. & Huber, K. M. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. *J. Neurophysiol.* **100**, 2615–2626 (2008).
34. Hays, S. A., Huber, K. M. & Gibson, J. R. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. *J. Neurosci.* **31**, 14223–14234 (2011).
35. Ronesi, J. A. et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. *Nat. Neurosci.* **15**, 431–440, S1 (2012).
36. Goncalves, J. T., Anstey, J. E., Golshani, P. & Portera-Cailliau, C. Circuit level defects in the developing neocortex of fragile X mice. *Nat. Neurosci.* **16**, 903–909 (2013).
37. Domanski, A. P. F., Booker, S. A., Wylie, D. J. A., Isaac, J. T. R. & Kind, P. C. Cellular and synaptic phenotypes lead to disrupted information processing in Fmr1-KO mouse layer 4 barrel cortex. *Nat. Commun.* **10**, 4814 (2019).
38. Goel, A. et al. Impaired perceptual learning in a mouse model of fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible. *Nat. Neurosci.* **21**, 1404–1411 (2018).
39. Garcia-Pino, E., Gesele, N. & Koch, U. Enhanced excitatory connectivity and disturbed sound processing in the auditory brainstem of fragile X mice. *J. Neurosci.* **37**, 7405–7419 (2017).
40. McCullagh, E. A., Salcedo, E., Huntsman, M. M. & Klug, A. Tonotopic alterations in inhibitory input to the medial nucleus of the trapezoid body in a mouse model of fragile X syndrome. *J. Comp. Neurol.* **525**, 3543–3562 (2017).
41. Rotschafer, S. E., Marshak, S. & Cramer, K. S. Deletion of Fmr1 alters function and synaptic inputs in the auditory brainstem. *PLoS ONE* **10**, e0117266 (2015).
42. Chuang, S. C. et al. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. *J. Neurosci.* **25**, 8048–8055 (2005).
43. Deng, P. Y. & Klyachko, V. A. Genetic upregulation of BK channel activity normalizes multiple synaptic and circuit defects in a mouse model of fragile X syndrome. *J. Physiol.* **594**, 83–97 (2016).
44. Wahlstrom-Helgren, S. & Klyachko, V. A. GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome. *J. Physiol.* **593**, 5009–5024 (2015).
45. Wahlstrom-Helgren, S. & Klyachko, V. A. Dynamic balance of excitation and inhibition rapidly modulates spike probability and precision in feed-forward hippocampal circuits. *J. Neurophysiol.* **116**, 2564–2575 (2016).
46. Martin, B. S., Corbin, J. G. & Huntsman, M. M. Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala. *J. Neurophysiol.* **112**, 890–902 (2014).
47. Martin, B. S. et al. Rescue of deficient amygdala tonic γ -aminobutyric acid currents in the Fmr^{-y} mouse model of fragile X syndrome by a novel γ -aminobutyric acid type A receptor-positive allosteric modulator. *J. Neurosci. Res.* **94**, 568–578 (2016).
48. Olmos-Serrano, J. L. et al. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. *J. Neurosci.* **30**, 9929–9938 (2010).
49. Vislay, R. L. et al. Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome. *J. Neurosci.* **33**, 7548–7558 (2013).
50. Suvrathan, A., Hoeffer, C. A., Wong, H., Klann, E. & Chattarji, S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. *Proc. Natl Acad. Sci. USA* **107**, 11591–11596 (2010).
51. Deng, P. Y. et al. Voltage-independent SK-channel dysfunction causes neuronal hyperexcitability in the hippocampus of Fmr1 knock-out mice. *J. Neurosci.* **39**, 28–43 (2019).
52. Deng, P. Y. & Klyachko, V. A. Increased persistent sodium current causes neuronal hyperexcitability in the entorhinal cortex of Fmr1 knockout mice. *Cell Rep.* **16**, 3157–3166 (2016).
53. **This study identifies Na⁺ channel dysregulation as a major cause of neuronal hyperexcitability in cortical FXS neurons and uncovers a mechanism via which increased mGluR5 signalling causes neuronal hyperexcitability in an FXS mouse model.**
54. El-Hassar, L. et al. Modulators of Kv3 potassium channels rescue the auditory function of fragile X Mice. *J. Neurosci.* **39**, 4797–4813 (2019).
55. Routh, B. N. et al. Increased transient Na⁺ conductance and action potential output in layer 2/3 prefrontal cortex neurons of the fmr1^{-y} mouse. *J. Physiol.* **595**, 4431–4448 (2017).
56. Meredith, R. M., Holmgren, C. D., Weidum, M., Burnashev, N. & Mansvelder, H. D. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. *Neuron* **54**, 627–638 (2007).
57. Brager, D. H., Akhavan, A. R. & Johnston, D. Impaired dendritic expression and plasticity of h-channels in the Fmr1^{-y} mouse model of fragile X syndrome. *Cell Rep.* **1**, 225–233 (2012).
58. **This study reports elevated dendritic expression of HCN channels coupled with impaired h-channel plasticity, which may underlie some of the cognitive impairments associated with FXS.**
59. Zhang, Y. et al. Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1^{-y} mice. *Nat. Neurosci.* **17**, 1701–1709 (2014).
60. **This study reveals dysfunctions of HCN and BK channels within the dendritic compartment, and provides evidence that BK channel openers have potential to address the sensory hypersensitivity aspects of FXS.**

58. Kalmbach, B. E., Johnston, D. & Brager, D. H. Cell-type specific channelopathies in the prefrontal cortex of the *Fmr1*^{-/-} mouse model of fragile X syndrome. *eNeuro* **2**, 0114–0115 (2015). **This study shows cell type-specific alterations in A-type K⁺ channels and HCN channels in two types of neighbouring neurons in the prefrontal cortex of *Fmr1* KO mice, which highlights the importance of understanding cell type-specific changes in neuronal excitability within the context of FXS.**
59. Booker, S. A. et al. Altered dendritic spine function and integration in a mouse model of fragile X syndrome. *Nat. Commun.* **10**, 4813 (2019).
60. Ferron, L., Nieto-Rostro, M., Cassidy, J. S. & Dolphin, A. C. Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density. *Nat. Commun.* **5**, 3628 (2014). **This study demonstrates that FMRP regulates surface expression of N-type VGCCs, and thus neurotransmitter release, in peripheral sensory neurons via protein–protein interactions.**
61. Ferron, L. et al. FMRP regulates presynaptic localization of neuronal voltage gated calcium channels. *Neurobiol. Dis.* **138**, 104779 (2020).
62. Deng, P. Y. et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. *Neuron* **77**, 696–711 (2013). **This study presents initial evidence that FMRP directly interacts with BK channels to regulate neurotransmitter release in central neurons, which provides the rationale for investigating the BK channel as a promising therapeutic target to treat numerous excitability-related deficits in FXS.**
63. Deng, P. Y., Sojka, D. & Klyachko, V. A. Abnormal presynaptic short-term plasticity and information processing in a mouse model of fragile X syndrome. *J. Neurosci.* **31**, 10971–10982 (2011).
64. Zhang, N. et al. Decreased surface expression of the δ subunit of the GABA_A receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome. *Exp. Neurol.* **297**, 168–178 (2017).
65. Yang, Y. M. et al. Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the fragile X brain. *Mol. Psychiatry* **25**, 2017–2035 (2018).
66. Curia, G., Papouin, T., Seguela, P. & Avoli, M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. *Cereb. Cortex* **19**, 1515–1520 (2009).
67. Darnell, J. C. et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. *Cell* **107**, 489–499 (2001).
68. Strumbos, J. G., Brown, M. R., Kronengold, J., Polley, D. B. & Kaczmarek, L. K. Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. *J. Neurosci.* **30**, 10263–10271 (2010).
69. Strumbos, J. G., Polley, D. B. & Kaczmarek, L. K. Specific and rapid effects of acoustic stimulation on the tonotopic distribution of Kv3.1b potassium channels in the adult rat. *Neuroscience* **167**, 567–572 (2010).
70. Rudy, B. & McBain, C. J. Kv3 channels: voltage-gated K⁺ channels designed for high-frequency repetitive firing. *Trends Neurosci.* **24**, 517–526 (2001).
71. Kim, G. E. & Kaczmarek, L. K. Emerging role of the KCNT1 Slack channel in intellectual disability. *Front. Cell Neurosci.* **8**, 209 (2014).
72. Brown, M. R. et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. *Nat. Neurosci.* **13**, 819–821 (2010). **This seminal study provides the first evidence that FMRP directly regulates ion channel activity through protein–protein interactions, which opens a new field investigating FMRP’s physiological role in controlling ion channel function.**
73. Zhang, Y. et al. Regulation of neuronal excitability by interaction of fragile X mental retardation protein with Slack potassium channels. *J. Neurosci.* **32**, 15318–15327 (2012).
74. Contet, C., Goulding, S. P., Kuljis, D. A. & Barth, A. L. BK channels in the central nervous system. *Int. Rev. Neurobiol.* **128**, 281–342 (2016).
75. Salkoff, L., Butler, A., Ferreira, G., Santi, C. & Wei, A. High-conductance potassium channels of the SLO family. *Nat. Rev. Neurosci.* **7**, 921–931 (2006).
76. Myrick, L. K. et al. Independent role for presynaptic FMRP revealed by an *FMR1* missense mutation associated with intellectual disability and seizures. *Proc. Natl Acad. Sci. USA* **112**, 949–956 (2015). **This study shows that loss of the translation-independent functions of FMRP is linked with a subset of FXS clinical features, suggesting that domain-specific functions of FMRP in presynaptic and postsynaptic compartments may contribute to different aspects of FXS pathophysiology.**
77. Hebert, B. et al. Rescue of fragile X syndrome phenotypes in *Fmr1* KO mice by a BKCa channel opener molecule. *Orphanet J. Rare Dis.* **9**, 124 (2014).
78. Short, B. FMRP differentially regulates BK channels. *J. Gen. Physiol.* **152**, e202012634 (2020).
79. Contractor, A. Broadening roles for FMRP: big news for big potassium (BK) channels. *Neuron* **77**, 601–603 (2013).
80. Kshatri, A. et al. Differential regulation of BK channels by fragile X mental retardation protein. *J. Gen. Physiol.* **152**, e201912502 (2020).
81. Telias, M., Kuznitsov-Yanovsky, L., Segal, M. & Ben-Yosef, D. Functional deficiencies in fragile X neurons derived from human embryonic stem cells. *J. Neurosci.* **35**, 15295–15306 (2015). **This study presents an extensive functional analysis of FXS neurons derived in vitro from embryonic stem cells of individuals with FXS that provides a useful tool for studying molecular mechanisms underlying the impaired neuronal functions in FXS.**
82. Diaz, J., Scheiner, C. & Leon, E. Presentation of a recurrent *FMR1* missense mutation (R138Q) in an affected female. *Transl Sci. Rare Dis.* **3**, 139–144 (2018).
83. Prieto, M. et al. Missense mutation of *Fmr1* results in impaired AMPAR-mediated plasticity and socio-cognitive deficits in mice. *Nat. Commun.* **12**, 1557 (2021).
84. Carreno-Munoz, M. I. et al. Potential involvement of impaired BKCa channel function in sensory defensiveness and some behavioral disturbances induced by unfamiliar environment in a mouse model of fragile X syndrome. *Neuropsychopharmacology* **43**, 492–502 (2018).
85. Bean, B. P. The action potential in mammalian central neurons. *Nat. Rev. Neurosci.* **8**, 451–465 (2007).
86. Dwivedi, D., Chatterji, S. & Bhalla, U. S. Impaired reliability and precision of spiking in adults but not juveniles in a mouse model of fragile X syndrome. *eNeuro* **6**, ENEURO.0217-19.2019 (2019).
87. Catterall, W. A. Voltage-gated calcium channels. *Cold Spring Harb. Perspect. Biol.* **3**, a003947 (2011).
88. Danesi, C. et al. Increased calcium influx through L-type calcium channels in human and mouse neural progenitors lacking fragile X mental retardation protein. *Stem Cell Rep.* **11**, 1449–1461 (2018).
89. Castagnola, S. et al. New insights into the role of Cav2 protein family in calcium flux deregulation in *Fmr1*-KO neurons. *Front. Mol. Neurosci.* **11**, 342 (2018).
90. Gray, E. E. et al. Disruption of Gpl mGluR-dependent Cav2.3 translation in a mouse model of fragile X syndrome. *J. Neurosci.* **39**, 7453–7464 (2019).
91. Zhan, X. et al. FMRP¹⁻²⁹⁷-*tat* restores ion channel and synaptic function in a model of fragile X syndrome. *Nat. Commun.* **11**, 2755 (2020). **This study shows that FMRP is part of a Cav3–Kv4 ion channel complex in cerebellar neurons, and describes a promising *tat*-conjugate approach to reintroduce an FMRP fragment to improve function in the cerebellum on multiple levels (channels, synapses, behaviour) in an FXS mouse model.**
92. Nanou, E., Scheuer, T. & Catterall, W. A. Calcium sensor regulation of the Cav2.1 Ca²⁺ channel contributes to long-term potentiation and spatial learning. *Proc. Natl Acad. Sci. USA* **113**, 13209–13214 (2016).
93. Cao, Y. Q. et al. Presynaptic Ca²⁺ channels compete for channel type-preferring slots in altered neurotransmission arising from Ca²⁺ channelopathy. *Neuron* **43**, 387–400 (2004).
94. Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* **146**, 247–261 (2011).
95. Gross, C., Yao, X., Pong, D. L., Jeromin, A. & Bassell, G. J. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. *J. Neurosci.* **31**, 5693–5698 (2011).
96. Lee, H. Y. et al. Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. *Neuron* **72**, 630–642 (2011). **Together with Gross et al. (2011), this study shows that FMRP regulates Kv4.2 channel expression with implications for altered dendritic excitability and plasticity in an FXS mouse model.**
97. Routh, B. N., Johnston, D. & Brager, D. H. Loss of functional A-type potassium channels in the dendrites of CA1 pyramidal neurons from a mouse model of fragile X syndrome. *J. Neurosci.* **33**, 19442–19450 (2013).
98. Chen, L., Yun, S. W., Seto, J., Liu, W. & Toth, M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. *Neuroscience* **120**, 1005–1017 (2003).
99. Gereau, R. W. T. & Conn, P. J. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. *J. Neurosci.* **15**, 6879–6889 (1995).
100. Shah, M. M. Cortical HCN channels: function, trafficking and plasticity. *J. Physiol.* **592**, 2711–2719 (2014).
101. Brandalise, F. et al. Fragile X mental retardation protein bidirectionally controls dendritic I_h in a cell-type specific manner between mouse hippocampus and prefrontal cortex. *J. Neurosci.* **40**, 5327–5340 (2020). **This study shows that FMRP regulates HCN channels via a cell-autonomous, protein–protein interaction and regulates its targets in opposite directions depending on the cellular milieu.**
102. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc. Natl Acad. Sci. USA* **99**, 7746–7750 (2002).
103. Li, J., Pelletier, M. R., Perez Velazquez, J. L. & Carlen, P. L. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. *Mol. Cell Neurosci.* **19**, 138–151 (2002).
104. Larson, J., Jessen, R. E., Kim, D., Fine, A. K. & du Hoffmann, J. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. *J. Neurosci.* **25**, 9460–9469 (2005).
105. Hu, H. et al. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. *J. Neurosci.* **28**, 7847–7862 (2008).
106. Lim, C. S. et al. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. *Genes Dev.* **28**, 273–289 (2014).
107. Guo, W. et al. Fragile X proteins FMRP and FXR2P control synaptic GluA1 expression and neuronal maturation via distinct mechanisms. *Cell Rep.* **11**, 1651–1666 (2015).
108. Berry-Kravis, E. et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. *J. Child Adolesc. Psychopharmacol.* **16**, 525–540 (2006).
109. Schutt, J., Falley, K., Richter, D., Kreienkamp, H. J. & Kindler, S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. *J. Biol. Chem.* **284**, 25479–25487 (2009).
110. Edbauer, D. et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. *Neuron* **65**, 373–384 (2010).
111. Yun, S. H. & Trommer, B. L. Fragile X mice: reduced long-term potentiation and N-methyl-D-aspartate receptor-mediated neurotransmission in dentate gyrus. *J. Neurosci. Res.* **89**, 176–182 (2011).
112. Bostrom, C. A. et al. Rescue of NMDAR-dependent synaptic plasticity in *Fmr1* knock-out mice. *Cereb. Cortex* **25**, 271–279 (2015).
113. Bostrom, C. et al. Hippocampal dysfunction and cognitive impairment in fragile-X syndrome. *Neurosci. Biobehav. Rev.* **68**, 563–574 (2016).
114. Eadie, B. D., Cushman, J., Kannangara, T. S., Fanselow, M. S. & Christie, B. R. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult *Fmr1* knockout mice. *Hippocampus* **22**, 241–254 (2012).
115. Yau, S. Y., Bettio, L., Chiu, J., Chiu, C. & Christie, B. R. Fragile-X syndrome is associated with NMDA receptor hypofunction and reduced dendritic complexity in mature dentate granule cells. *Front. Mol. Neurosci.* **11**, 495 (2019).

116. Smart, T. G. & Stephenson, F. A. A half century of γ -aminobutyric acid. *Brain Neurosci. Adv.* **3**, 2398212819858249 (2019).
117. Van der Aa, N. & Kooy, R. F. GABAergic abnormalities in the fragile X syndrome. *Eur. J. Paediatr. Neurol.* **24**, 100–104 (2020).
118. Gantois, I. et al. Expression profiling suggests underexpression of the GABA_A receptor subunit δ in the fragile X knockout mouse model. *Neurobiol. Dis.* **21**, 346–357 (2006).
119. D'Hulst, C. et al. Decreased expression of the GABA_A receptor in fragile X syndrome. *Brain Res.* **1121**, 238–245 (2006).
- Together with Gantois et al. (2006), this study reports hypofunction of GABA_ARs in an FXS mouse model, which points to the GABA_AR as a promising target for treatment of the behavioural and epileptic phenotypes associated with FXS.**
120. Sabanov, V. et al. Impaired GABAergic inhibition in the hippocampus of Fmr1 knockout mice. *Neuropharmacology* **116**, 71–81 (2017).
121. Vien, T. N. et al. Compromising the phosphodependent regulation of the GABA_AR $\beta 3$ subunit reproduces the core phenotypes of autism spectrum disorders. *Proc. Natl Acad. Sci. USA* **112**, 14805–14810 (2015).
122. D'Hulst, C., Attack, J. R. & Kooy, R. F. The complexity of the GABA_A receptor shapes unique pharmacological profiles. *Drug Discov. Today* **14**, 866–875 (2009).
123. Adusei, D. C., Pacey, L. K., Chen, D. & Hampson, D. R. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. *Neuropharmacology* **59**, 167–171 (2010).
124. El Idrissi, A. et al. Decreased GABA_A receptor expression in the seizure-prone fragile X mouse. *Neurosci. Lett.* **377**, 141–146 (2005).
125. D'Hulst, C. et al. Positron emission tomography (PET) quantification of GABA_A receptors in the brain of fragile X patients. *PLoS ONE* **10**, e0131486 (2015).
126. Braat, S. et al. The GABA_A receptor is an FMRP target with therapeutic potential in fragile X syndrome. *Cell Cycle* **14**, 2985–2995 (2015).
127. Davidovic, L. et al. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. *Genome Res.* **21**, 2190–2202 (2011).
128. Huntsman, M. M. & Kooy, R. F. in *Fragile X Syndrome: From Genetics to Targeted Treatment* (eds Willemsen, R. & Kooy, R. F.) 205–215 (Academic Press, 2017).
129. Braat, S. & Kooy, R. F. Insights into GABA_Aergic system deficits in fragile X syndrome lead to clinical trials. *Neuropharmacology* **88**, 48–54 (2014).
130. Hutson, R. L., Thompson, R. L., Bantel, A. P. & Tessier, C. R. Acamprostate rescues neuronal defects in the *Drosophila* model of fragile X syndrome. *Life Sci.* **195**, 65–70 (2018).
131. Schaefer, T. L. et al. Acamprostate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety. *J. Neurodev. Disord.* **9**, 6 (2017).
132. Erickson, C. A., Mullett, J. E. & McDougle, C. J. Brief report: acamprostate in fragile X syndrome. *J. Autism Dev. Disord.* **40**, 1412–1416 (2010).
133. Erickson, C. A. et al. Impact of acamprostate on plasma amyloid- β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. *J. Psychiatr. Res.* **59**, 220–228 (2014).
134. Ligsay, A. et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. *J. Neurodev. Disord.* **9**, 26 (2017).
135. Di Miceli, M. & Gronier, B. Pharmacology, systematic review and recent clinical trials of metadoxine. *Rev. Recent Clin. Trials* **13**, 114–125 (2018).
136. Silverman, J. L. et al. GABA_B receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. *Neuropsychopharmacology* **40**, 2228–2239 (2015).
137. Sinclair, D. et al. GABA-B agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of fragile X syndrome. *eNeuro* **4**, ENEURO.0380-16.2017 (2017).
138. Stoppel, L. J. et al. R-Baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11.2 deletion mice. *Neuropsychopharmacology* **43**, 513–524 (2018).
139. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA_B receptors with arbaclofen. *Sci. Transl. Med.* **4**, 152ra128 (2012).
140. Berry-Kravis, E. M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Sci. Transl. Med.* **4**, 152ra127 (2012).
141. Erickson, C. A. et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. *J. Autism Dev. Disord.* **44**, 958–964 (2014).
142. Represa, A. & Ben-Ari, Y. Trophic actions of GABA on neuronal development. *Trends Neurosci.* **28**, 278–283 (2005).
143. Liu, R., Wang, J., Liang, S., Zhang, G. & Yang, X. Role of NKCC1 and KCC2 in epilepsy: from expression to function. *Front. Neurol.* **10**, 1407 (2020).
144. He, Q., Nomura, T., Xu, J. & Contractor, A. The developmental switch in GABA polarity is delayed in fragile X mice. *J. Neurosci.* **34**, 446–450 (2014).
145. He, Q. et al. Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice. *Mol. Psychiatry* **24**, 1732–1747 (2019).
- Together with He et al. (2014), this study provides strong evidence that targeting the Cl⁻ transporter NKCC1 during the critical period restores synapse development in cortical neurons and produces a long-lasting correction of somatosensory circuit function in FXS mice.**
146. Tyzio, R. et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. *Science* **343**, 675–679 (2014).
147. Hodges, J. L. et al. Astrocytic contributions to synaptic and learning abnormalities in a mouse model of fragile X syndrome. *Biol. Psychiatry* **82**, 139–149 (2017).
148. Cheng, C., Lau, S. K. & Doering, L. C. Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model. *Mol. Brain* **9**, 74 (2016).
149. Higashimori, H. et al. Selective deletion of astroglial FMRP dysregulates glutamate transporter GLT1 and contributes to fragile X syndrome phenotypes in vivo. *J. Neurosci.* **36**, 7079–7094 (2016).
150. Guglielmi, L. et al. Update on the implication of potassium channels in autism: K⁺ channel autism spectrum disorder. *Front. Cell Neurosci.* **9**, 34 (2015).
151. Schmunk, G. & Gargus, J. J. Channelopathy pathogenesis in autism spectrum disorders. *Front. Genet.* **4**, 222 (2013).
152. Lee, H., Lin, M. C., Kornblum, H. I., Papazian, D. M. & Nelson, S. F. Exome sequencing identifies de novo gain of function missense mutation in KCND2 in identical twins with autism and seizures that slows potassium channel inactivation. *Hum. Mol. Genet.* **23**, 3481–3489 (2014).
153. Lin, M. A., Cannon, S. C. & Papazian, D. M. Kv4.2 autism and epilepsy mutation enhances inactivation of closed channels but impairs access to inactivated state after opening. *Proc. Natl Acad. Sci. USA* **115**, E3559–E3568 (2018).
154. Laumonnier, F. et al. Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation. *Am. J. Psychiatry* **163**, 1622–1629 (2006).
155. Kruth, K. A., Grisolan, T. M., Ahern, C. A. & Williams, A. J. SCN2A channelopathies in the autism spectrum of neuropsychiatric disorders: a role for pluripotent stem cells? *Mol. Autism* **11**, 23 (2020).
156. Orefice, L. L. et al. Targeting peripheral somatosensory neurons to improve tactile-related phenotypes in ASD models. *Cell* **178**, 867–886 (2019).
- This study reveals a potential therapeutic strategy targeting excitation/inhibition imbalance in peripheral mechanosensory circuits to treat tactile over-reactivity and select ASD-related behaviours.**
157. Liao, L., Park, S. K., Xu, T., Vanderklish, P. & Yates, J. R. 3rd Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in Fmr1 knockout mice. *Proc. Natl Acad. Sci. USA* **105**, 15281–15286 (2008).
158. Myrick, L. K., Hashimoto, H., Cheng, X. & Warren, S. T. Human FMRP contains an integral tandem Agenet (Tudor) and KH motif in the amino terminal domain. *Hum. Mol. Genet.* **24**, 1733–1740 (2015).

Acknowledgements

This work was supported in part by R35 grant NS111596 to V.A.K. from the National Institute of Neurological Disorders and Stroke (NINDS). The authors apologize to colleagues whose work could not be cited in this Review due to space limitations. Figures 1 and 2 were created with BioRender.com.

Author contributions

P.-Y.D. and V.A.K. contributed equally to this work.

Competing interests

The authors declare no competing interests

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Referee accreditation

Nature Reviews Neuroscience thanks L. Kaczmarek and R. Hagerman, and the other anonymous reviewer(s), for their contribution to the peer review of this work.

© Springer Nature Limited 2021